A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging

INTRODUCTION: Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development of Alzheimer's brain pathology. Robust tau and Aβ42 immunoassays were developed to establish a tau/Aβ42 cutoff distinguishing mild-to-moderate Alzheimer's disease (AD) subjects from healthy el...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Alzheimers Dement (Amst)
Prif Awduron: Mo, Yi, Stromswold, Julie, Wilson, Kimberly, Holder, Daniel, Sur, Cyrille, Laterza, Omar, Savage, Mary J., Struyk, Arie, Scheltens, Philip, Teunissen, Charlotte E., Burke, James, Macaulay, S. Lance, Bråthen, Geir, Sando, Sigrid Botne, White, Linda R., Weiss, Christy, Cowes, Arturo, Bush, Michele M., DeSilva, Ganga, Darby, David G., Rainey-Smith, Stephanie R., Surls, Jackie, Sagini, Eileen, Tanen, Michael, Altman, Amy, Luthman, Johan, Egan, Michael F.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier 2017
Pynciau:
CSF Biomarkers
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5357677/
https://ncbi.nlm.nih.gov/pubmed/28349119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dadm.2017.02.004
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg